CONMED Corp. 10-Q Summary: Quarter Ended September 30, 2004
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2004, for CONMED Corporation, a medical technology company specializing in instruments, implants, and video equipment for arthroscopic sports medicine, powered surgical instruments, and electrosurgery. The company operates through four principal units: CONMED Patient Care, CONMED Endosurgery, CONMED Electrosurgery, and Linvatec Corporation. International sales accounted for 35% of total net sales for the nine-month period.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 |
|---|---|---|
| Net Sales | $132,289 | $397,165 |
| Gross Profit | $67,487 | $206,560 |
| Gross Margin | 51.0% | 52.0% |
| Operating Income | $5,495 | $48,791 |
| Net Income | $1,699 | $26,030 |
| Diluted EPS | $0.06 | $0.86 |
| Cash from Operations (9mo) | $57,941 | |
| Total Debt (Long-term + Current) | $289,983 | |
| Cash and Equivalents | $10,223 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.6% ($11.6 million) in the quarter and 9.3% ($33.9 million) year-to-date compared to 2003. Growth was driven by Arthroscopy (+19.0% Q/Q), Patient Care (+9.4% Q/Q), and Electrosurgery (+2.9% Q/Q).
- Profitability Impact: Despite revenue growth, Net Income for the quarter dropped significantly from $9.7 million in 2003 to $1.7 million in 2004. This was primarily due to a $13.7 million write-off of purchased in-process research and development (IPRD) assets related to the Bard Endoscopic Technologies acquisition.
- Operating Expenses: Selling and administrative expenses increased to $42.7 million (32.3% of sales) from $38.6 million (32.0% of sales) due to sales force restructuring, legal costs for antitrust litigation against Johnson & Johnson, and Sarbanes-Oxley compliance.
- Interest Expense: Interest expense decreased to $3.2 million in the quarter (from $3.8 million) and $9.1 million year-to-date (from $15.2 million) due to lower average interest rates and the redemption of $130 million in senior notes in 2003.
Guidance, Outlook, and Risks
- Acquisition Integration: The company completed the acquisition of C.R. Bard's Endoscopic Technologies Division for $80 million on September 30, 2004. Manufacturing is expected to shift to CONMED facilities within 6-9 months.
- Capital Markets: On November 4, 2004, CONMED announced a private placement of $125 million in 2.50% convertible senior subordinated notes due 2024. Proceeds are intended to repay $90 million of senior credit agreement borrowings and repurchase $30 million of common stock.
- Legal Proceedings: The company is engaged in antitrust litigation against Johnson & Johnson regarding endoscopic surgery products. While claims are covered by insurance where applicable, the company notes that costs associated with patent litigation could be material.
- Risks: Key risks include the ability to integrate acquired businesses, regulatory approvals for new products (specifically Pro2 and ECOM devices), and potential impairment of goodwill or intangible assets.
Investor Verification Checklist
- IPRD Write-off: Verify the tax deductibility and future commercial viability of the $13.7 million Bard IPRD write-off, which heavily impacted Q3 earnings.
- Debt Structure: Confirm the terms and impact of the new $125 million convertible note offering on future dilution and interest obligations.
- Margin Pressure: Monitor gross margin trends as the company shifts product mix toward lower-margin video imaging and patient care products.
- Legal Exposure: Track the status and potential cost of the antitrust lawsuit against Johnson & Johnson.
- Acquisition Synergies: Assess the timeline and cost savings associated with transitioning Bard Endoscopic Technologies manufacturing to CONMED facilities.